Breathe Well Live Well
News24 |
Nyaope, asthma to blame for initiation deaths in Mpumalanga – traditional authorities
News24 Mbombela – Mpumalanga traditional authorities have blamed nyaope and asthma for the deaths of two initiates in the province recently. The first initiate died at an initiation school in Emalahleni, while the other died in Verena. "Both these initiates … |
View full post on asthma – Google News
|
Initiation of Inhaled Corticosteroid and Long-Acting b2-adrenergic Agonist …
AJMC.com Managed Markets Network Study Design: The current study is a retrospective cohort analysis of patients with asthma, aged 12 to 64 years, new to ICS/LABA combination therapy, using—US healthcare claims data between June 1, 2007, and December 31, 2010. Methods: Patients with … |
View full post on asthma – Google News
|
INVION LTD : Invion announces initiation of phase II asthma study
4-traders Invion Limited (ASX:IVX), a clinical-stage drug development company targeting chronic inflammation, today announced the initiation of "NIMA", a phase II clinical trial that is funded by the US National Institute of Allergy and Infectious Diseases … |
View full post on asthma – Google News
|
iSonea Announces Initiation of Pediatric Asthma Study
Virtual-Strategy Magazine The goal of the Wheeze Rate Correlation Study is to assess wheeze rate in pediatric patients with a range of asthma symptom severity. Although the WheezoMeter has been studied previously, this is the first large US study of the WheezoMeter in a … |
View full post on asthma – Google News
|
Trident Pharmaceuticals Announces Initiation Of Phase 1a
Pharmaceutical Online (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News
|
Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020
MarketWatch (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
EON: Enhanced Online News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … Targacept to begin phase 2 trials for its anti-inflammatory drug compound Targacept starts new trial for diabetes drug |
View full post on asthma – Google News
|
TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
4-traders (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
Genetic Engineering News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
In humans, throwing a ball, typing on a keyboard, or engaging in most other physical activities involves the coordination of numerous discrete movements that are organized as action sequences. Scientists at the National Institutes of Health and the Gulbenkian Institute in Portugal have identified brain activity in mice that can signal the initiation and termination of newly learned action sequences. The findings appear online today in the current issue of Nature.
View full post on National Institutes of Health (NIH) News Releases